Thursday, April 10, 2008 7:01:03 AM
Wednesday April 9, 10:27 am ET
Schering-Plough Ends Partnership With Novacea on Failed Cancer Drug Candidate
SOUTH SAN FRANCISCO, Calif. (AP) -- Schering-Plough Corp. has ended its partnership with Novacea Inc. after their prostate cancer drug candidate Asentar failed, Novacea said Wednesday.
Novacea shares plunged 40 cents, or 14.8 percent, to $2.31 in morning trading. The stock has traded between $2.20 and $17.25 over the last 52 weeks.
The companies ended a late-stage study of the drug in November, citing an "imbalance" of deaths. Patients taking the drug candidate died more often than those taking a standard treatment.
In January, Novacea said it is exploring "strategic options" and retained Cowen and Co. as an adviser.
All Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM